IMMUTEP Ltd (IMMP) Form 20-F — Oct 23, 2026
Immutep filed its FY2026 annual report (fiscal year ended June 30, 2026) showing a net loss of A$79.3 million, widened from A$61.4 million a year earlier, with no products approved for commercial sale. The most significant clinical development was the March 2026 discontinuation of TACTI-004, the registrational Phase III trial of lead asset eftilagimod alfa in 1st line NSCLC, after a planned interim futility analysis. This triggered an A$3.1 million non-cash impairment of efti-related IP, and an ongoing root cause analysis identified subtle structural differences between 2,000L and 200L scale manufactured efti as potentially relevant to the failed outcome.
Key figures
- Employees
- 46
- Ads ratio new
- 1 ADS = 200 ordinary shares (effective September 28, 2026)
- Ads ratio prior
- 1 ADS = 10 ordinary shares
- Fx gain fy2026 aud
- A$1.23 million
- Net loss fy2025 aud
- A$61.4 million
- Net loss fy2026 aud
- A$79.3 million
- Asx share price range
- A$0.028 - A$0.47
- Impairment charge aud
- A$3.1 million
- Nasdaq ads price range
- US$0.29 - US$3.53
- Prior year net loss aud
- 61400000
- Milestones dr reddys usd
- up to US$349.5 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.